David Hoang
Stock Analyst at Deutsche Bank
(2.93)
# 1,647
Out of 5,055 analysts
47
Total ratings
45.95%
Success rate
0.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Hoang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALKS Alkermes | Maintains: Buy | $55 → $45 | $29.33 | +53.43% | 3 | Nov 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $280 | $197.58 | +41.71% | 2 | Oct 17, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $43 | $24.36 | +76.52% | 1 | Sep 26, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $54 → $36 | $33.97 | +5.98% | 4 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Sell | $6 → $12 | $17.54 | -31.58% | 10 | Aug 15, 2025 | |
| ACAD ACADIA Pharmaceuticals | Upgrades: Buy | $20 → $35 | $24.01 | +45.77% | 5 | May 21, 2025 | |
| XENE Xenon Pharmaceuticals | Initiates: Buy | $67 | $40.61 | +64.98% | 3 | Feb 11, 2025 | |
| DNLI Denali Therapeutics | Initiates: Buy | $31 | $17.37 | +78.47% | 3 | Feb 11, 2025 | |
| BHVN Biohaven | Initiates: Buy | $65 | $8.27 | +685.97% | 1 | Feb 11, 2025 | |
| AXSM Axsome Therapeutics | Initiates: Buy | $176 | $145.56 | +20.91% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $23.02 | -47.87% | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $150 → $158 | $143.56 | +10.06% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.58 | +343.04% | 1 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.34 | +268.66% | 1 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $4.11 | +289.29% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $220 | $460.54 | -52.23% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $40.15 | +99.25% | 1 | Apr 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $2.99 | +0.33% | 1 | Dec 7, 2022 |
Alkermes
Nov 13, 2025
Maintains: Buy
Price Target: $55 → $45
Current: $29.33
Upside: +53.43%
Praxis Precision Medicines
Oct 17, 2025
Maintains: Buy
Price Target: $65 → $280
Current: $197.58
Upside: +41.71%
Spyre Therapeutics
Sep 26, 2025
Initiates: Buy
Price Target: $43
Current: $24.36
Upside: +76.52%
Harmony Biosciences Holdings
Sep 25, 2025
Maintains: Buy
Price Target: $54 → $36
Current: $33.97
Upside: +5.98%
Sarepta Therapeutics
Aug 15, 2025
Maintains: Sell
Price Target: $6 → $12
Current: $17.54
Upside: -31.58%
ACADIA Pharmaceuticals
May 21, 2025
Upgrades: Buy
Price Target: $20 → $35
Current: $24.01
Upside: +45.77%
Xenon Pharmaceuticals
Feb 11, 2025
Initiates: Buy
Price Target: $67
Current: $40.61
Upside: +64.98%
Denali Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $31
Current: $17.37
Upside: +78.47%
Biohaven
Feb 11, 2025
Initiates: Buy
Price Target: $65
Current: $8.27
Upside: +685.97%
Axsome Therapeutics
Feb 11, 2025
Initiates: Buy
Price Target: $176
Current: $145.56
Upside: +20.91%
Feb 11, 2025
Initiates: Buy
Price Target: $12
Current: $23.02
Upside: -47.87%
Aug 2, 2024
Maintains: Neutral
Price Target: $150 → $158
Current: $143.56
Upside: +10.06%
Jul 25, 2024
Initiates: Buy
Price Target: $7
Current: $1.58
Upside: +343.04%
Mar 15, 2024
Initiates: Buy
Price Target: $16
Current: $4.34
Upside: +268.66%
Mar 7, 2024
Initiates: Buy
Price Target: $16
Current: $4.11
Upside: +289.29%
Apr 26, 2023
Initiates: Neutral
Price Target: $220
Current: $460.54
Upside: -52.23%
Apr 26, 2023
Initiates: Outperform
Price Target: $80
Current: $40.15
Upside: +99.25%
Dec 7, 2022
Downgrades: Neutral
Price Target: $3
Current: $2.99
Upside: +0.33%